SUBSCRIBE
SUBSCRIBE

Travere Therapeutics

NEWS
Biotech Beach
Retrophin Announces Upcoming Presentations at the 15th International Symposium on IgA Nephropathy
Retrophin, Inc. today announced two upcoming presentations related to its development program for sparsentan in the treatment of IgA nephropathy
September 30, 2018
 · 
8 min read
Biotech Beach
Retrophin to Present at Upcoming October 2018 Investor Conferences
Retrophin, Inc. (NASDAQ: RTRX) today announced that the Company’s management team will present at the following upcoming investor conferences in October
September 19, 2018
 · 
1 min read
Biotech Vets Launch Arrakis With $38 Million and Will be Helmed By Biogen Alum Michael Gilman
Job Trends
Retrophin to Close Down Cambridge Operations, Cut Jobs in Consolidation Move
March 9, 2017
 · 
2 min read
Business
Retrophin’s R&D Head Resigns to Helm Unnamed Biotech Startup
October 6, 2016
 · 
2 min read
Policy
Retrophin Sues Ousted CEO Martin Shkreli for $65 Million
August 17, 2015
 · 
2 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Business
Former Retrophin CEO Nabs $90 Million for Startup Turing Pharma
August 10, 2015
 · 
3 min read
Business
Ousted Retrophin CEO Martin Shkreli Launches Turing
February 24, 2015
 · 
3 min read
Policy
More Trouble for Retrophin Founder
January 8, 2015
 · 
2 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Policy
Ex-Retrophin CEO Sold Stock While Urging Investors To Buy
November 26, 2014
 · 
2 min read
Load More
JOBS
IN THE PRESS
Biotech Beach
Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations
January 25, 2024
 · 
14 min read
Biotech Beach
Travere Therapeutics Provides Corporate Update and 2024 Outlook
January 8, 2024
 · 
15 min read
Biotech Beach
Travere Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 2, 2024
 · 
1 min read
Drug Development
Travere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase for the Treatment of Classical Homocystinuria (HCU)
December 14, 2023
 · 
9 min read
Biotech Beach
Travere Completes Successful pre-NDA Meeting for FILSPARI in IgAN; Provides Regulatory Updates for both IgAN and FSGS
December 4, 2023
 · 
20 min read
Biotech Beach
Travere Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference
November 21, 2023
 · 
1 min read
Business
Travere Therapeutics Reports Third Quarter 2023 Financial Results
November 7, 2023
 · 
27 min read
Biotech Beach
Travere Therapeutics Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and FSGS Published in The Lancet and The NEJM Respectively and Presented at the American Society of Nephrology (ASN) Kidney Week 2023
November 3, 2023
 · 
21 min read
Business
Travere Therapeutics to Report Third Quarter 2023 Financial Results
October 24, 2023
 · 
1 min read
Biotech Beach
Travere Therapeutics to Present Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023
October 13, 2023
 · 
20 min read
Load More